Yahoo · Aug 14, 2026
Cryoport (CYRX) Q2 2026 Earnings Call Transcript
CGT services revenue surged 15% as clinical trial support expanded to 779 trials globally.
CY
NASDAQ · CYRX
Cryoport, Inc.
Industrials · Integrated Freight & Logistics
$16.09
Down-$0.48 (-2.90%)
Updated Aug 29, 2026, 11:59 AM
SID Score
7.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 482.65M
- P/E ratio
- 7.15
- Dividend yield
- 0.00%
- 52-week range
- $7.64 – $17.20
- Volume
- 431.16K
- Avg. volume
- 672.11K
Price performance
CYRX price history
1M range · 21 trading sessions · Daily adjusted prices
CYRX closed at $16.09 after 21 trading sessions, up 6.63% for the selected period.
- Last close
- $16.09
- Period change
- +6.63%
- Period low
- $14.71
- Period high
- $17.13
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $16.54 | $16.625 | $15.85 | $16.09 | 431.16K |
| Aug 27, 2026 | $16.49 | $16.905 | $16.4702 | $16.57 | 328.67K |
| Aug 26, 2026 | $16.57 | $17.08 | $16.265 | $16.57 | 267.33K |
| Aug 25, 2026 | $16.51 | $16.94 | $16.42 | $16.72 | 476.78K |
| Aug 24, 2026 | $17.00 | $17.005 | $16.10 | $16.34 | 493.27K |
| Aug 21, 2026 | $16.80 | $17.20 | $16.33 | $17.13 | 1.03M |
| Aug 20, 2026 | $16.07 | $16.83 | $16.07 | $16.71 | 879.06K |
| Aug 19, 2026 | $15.40 | $16.58 | $15.40 | $16.31 | 999.29K |
| Aug 18, 2026 | $15.23 | $15.33 | $14.88 | $15.09 | 456.22K |
| Aug 17, 2026 | $15.15 | $15.38 | $15.04 | $15.32 | 382.78K |
| Aug 14, 2026 | $15.00 | $15.35 | $14.80 | $15.25 | 345.47K |
| Aug 13, 2026 | $14.96 | $15.34 | $14.82 | $15.13 | 394.53K |
| Aug 12, 2026 | $14.96 | $15.02 | $14.60 | $14.80 | 425.48K |
| Aug 11, 2026 | $15.03 | $15.19 | $14.61 | $14.95 | 624.76K |
| Aug 10, 2026 | $14.86 | $15.07 | $14.35 | $14.82 | 614.77K |
| Aug 7, 2026 | $15.22 | $15.42 | $14.32 | $15.12 | 1.07M |
| Aug 6, 2026 | $15.31 | $15.325 | $14.67 | $14.71 | 635.07K |
| Aug 5, 2026 | $15.22 | $15.42 | $15.05 | $15.25 | 363.99K |
| Aug 4, 2026 | $15.50 | $15.60 | $15.09 | $15.22 | 581.1K |
| Aug 3, 2026 | $15.15 | $15.50 | $14.99 | $15.49 | 424.4K |
| Jul 31, 2026 | $15.32 | $15.325 | $14.85 | $15.09 | 396.08K |
Latest CYRX news
The latest Smart Investors Daily articles mentioning CYRX.
Stock researchCompany · Overview
CYRX research
Overview
Company profile and research snapshot.
Company profile
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $13.75
- Implied upside
- —
- Analysts
- 15
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Guggenheim | Buy | — |
| Aug 7, 2026 | Needham | Buy | — |
| Jul 24, 2026 | BTIG | Buy | — |
| Jun 3, 2026 | Craig-Hallum | Buy | — |
| May 20, 2026 | Keybanc | Overweight | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 7, 2026
Cryoport, Inc. (CYRX) Q2 2026 Earnings Call Transcript
Cryoport, Inc. (CYRX) Q2 2026 Earnings Call August 6, 2026 5:00 PM EDTCompany ParticipantsJerrell Shelton - Chairman, President & CEORobert Stefanovich...
Benzinga · Aug 7, 2026
Guggenheim Maintains Buy on CryoPort, Raises Price Target to $16
Guggenheim analyst Subbu Nambi maintains CryoPort (NASDAQ:CYRX) with a Buy and raises the price target from $12 to $16.
Benzinga · Aug 7, 2026
Needham Maintains Buy on CryoPort, Raises Price Target to $19
Needham analyst David Saxon maintains CryoPort (NASDAQ:CYRX) with a Buy and raises the price target from $15 to $19.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
